The WACC of Kalbe Farma Tbk PT (KLBF.JK) is 12.6%.
Range | Selected | |
Cost of equity | 11.5% - 13.7% | 12.6% |
Tax rate | 22.7% - 22.9% | 22.8% |
Cost of debt | 5.0% - 5.0% | 5% |
WACC | 11.5% - 13.6% | 12.6% |
Category | Low | High |
Long-term bond rate | 6.6% | 7.1% |
Equity market risk premium | 7.9% | 8.9% |
Adjusted beta | 0.62 | 0.69 |
Additional risk adjustments | 0.0% | 0.5% |
Cost of equity | 11.5% | 13.7% |
Tax rate | 22.7% | 22.9% |
Debt/Equity ratio | 0.01 | 0.01 |
Cost of debt | 5.0% | 5.0% |
After-tax WACC | 11.5% | 13.6% |
Selected WACC | 12.6% | |
Debt/Equity | Unlevered | |||
Peers | Company Name | ratio | Beta | beta |
KLBF.JK | Kalbe Farma Tbk PT | 0.01 | 0.66 | 0.66 |
000513.SZ | Livzon Pharmaceutical Group Inc | 0.13 | 0.62 | 0.57 |
4530.T | Hisamitsu Pharmaceutical Co Inc | 0.01 | 0.13 | 0.13 |
DVLA.JK | Darya-Varia Laboratoria Tbk PT | 0 | 0.46 | 0.46 |
KAEF.JK | Kimia Farma Tbk PT | 2.05 | 1.3 | 0.5 |
MERK.JK | Merck Tbk PT | 0.02 | 0.39 | 0.39 |
PEHA.JK | Phapros Tbk PT | 2.83 | 0.89 | 0.28 |
PYFA.JK | Pyridam Farma Tbk PT | 1.43 | 1.52 | 0.72 |
SOHO.JK | SOHO Global Health PT | 0 | 0.36 | 0.36 |
TSPC.JK | Tempo Scan Pacific Tbk PT | 0.08 | 0.69 | 0.64 |
Low | High | |
Unlevered beta | 0.43 | 0.53 |
Relevered beta | 0.43 | 0.54 |
Adjusted relevered beta | 0.62 | 0.69 |
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for KLBF.JK:
cost_of_equity (12.60%) = risk_free_rate (6.85%) + equity_risk_premium (8.40%) * adjusted_beta (0.62) + risk_adjustments (0.25%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.